Susana Campos is an Oncology physician affiliated with Dana-Farber Cancer Institute. OpenAlex indexes 179 publications with 9,475 citations (h-index 44); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
44 Binney St
Dana-Farber Cancer Institute
Boston, MA 02115
Telephone
617-632-5269Registry record last updated 8 Jul 2007.
Clinical trials
- Tivozanib As Maintenance Therapy In GYN
Sponsor: Dana-Farber Cancer Institute
- Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Sponsor: National Cancer Institute (NCI)
- AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Sponsor: Susana M. Campos, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20256 payments$17,067openpaymentsdata.cms.gov ↗
- Genmab U.S., Inc.Program year202522 payments$14,816openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Journal of the National Comprehensive Cancer Network
2025 - Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023 - NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Journal of the National Comprehensive Cancer Network
2023 - A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”